Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals Inc (AMPH)
:AMPH
RESEARCH TOOLSreports
Holding AMPH?
Track your performance easily
AMPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$34.60 - $56.88
Previous CloseN/A
Volume255.86K
Average Volume (3M)644.88K
Market Cap
$1.71B
Enterprise Value$2.89B
Total Cash (Recent Filing)$72.88M
Total Debt (Recent Filing)$32.36M
Price to Earnings (P/E)11.9
Beta0.78
Next Earnings
Mar 12, 2025EPS Estimate
0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.00
Shares Outstanding48,081,432
10 Day Avg. Volume704,445
30 Day Avg. Volume644,881
Standard Deviation0.12
R-Squared0.14
Alpha0.00812
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.41
Price to Cash Flow (P/CF)7.30
P/FCF Ratio9.40
Enterprise Value/Market Cap1.69
Enterprise Value/Revenue4.00
Enterprise Value/Gross Profit8.24
Enterprise Value/Ebitda10.87
Forecast
1Y Price Target
$63.67Price Target Upside78.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Amphastar Pharmaceuticals News
PremiumCompany Announcements
Amphastar Pharmaceuticals Reports Strong Q3 2024 Results
PremiumCompany Announcements
Amphastar Pharmaceuticals Advances Governance and Shareholder Value
Bulls Say, Bears Say
Bulls Say
Commercial StrategyAMPH's focus on complex generics, biosimilars, and proprietary brands highlights a differentiated commercial strategy aimed at capturing niche markets.
Financial HealthAmphastar demonstrates strong financial health with substantial cash reserves and a low net leverage ratio, supporting potential business expansion.
Product LaunchesAMPH could have multiple new product approvals and launches, signaling a robust pipeline and growth potential.
Bears Say
Financial PerformanceFinancial results fell short of market expectations on both revenue and profit measures.
Regulatory IssuesRegulatory actions have delayed potential product launches, contributing to the stock's underperformance.
Supply Chain ProblemsSupply issues with Baqsimi significantly impacted European sales figures.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AMPH FAQ
What was Amphastar Pharmaceuticals Inc’s price range in the past 12 months?
Amphastar Pharmaceuticals Inc lowest stock price was $34.60 and its highest was $56.88 in the past 12 months.
What is Amphastar Pharmaceuticals Inc’s market cap?
Amphastar Pharmaceuticals Inc’s market cap is $1.71B.
When is Amphastar Pharmaceuticals Inc’s upcoming earnings report date?
Amphastar Pharmaceuticals Inc’s upcoming earnings report date is Mar 12, 2025 which is in 53 days.
How were Amphastar Pharmaceuticals Inc’s earnings last quarter?
Amphastar Pharmaceuticals Inc released its earnings results on Nov 06, 2024. The company reported $0.96 earnings per share for the quarter, missing the consensus estimate of $0.988 by -$0.028.
Is Amphastar Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals Inc’s price is currently Undervalued.
Does Amphastar Pharmaceuticals Inc pay dividends?
Amphastar Pharmaceuticals Inc does not currently pay dividends.
What is Amphastar Pharmaceuticals Inc’s EPS estimate?
Amphastar Pharmaceuticals Inc’s EPS estimate is 0.96.
How many shares outstanding does Amphastar Pharmaceuticals Inc have?
Amphastar Pharmaceuticals Inc has 48,081,432 shares outstanding.
What happened to Amphastar Pharmaceuticals Inc’s price movement after its last earnings report?
Amphastar Pharmaceuticals Inc reported an EPS of $0.96 in its last earnings report, missing expectations of $0.988. Following the earnings report the stock price went down -13.689%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals Inc?
Among the largest hedge funds holding Amphastar Pharmaceuticals Inc’s share is Hotchkis & Wiley Capital Management LLC. It holds Amphastar Pharmaceuticals Inc’s shares valued at 11M.
---
Amphastar Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.67 (78.55% Upside)
$63.67 (78.55% Upside)
Blogger Sentiment
Bullish
AMPH Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 166.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.74%
12-Months-Change
Fundamentals
Return on Equity
23.85%
Trailing 12-Months
Asset Growth
0.04%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
---
AMPH Company Deck
---
AMPH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a mixed picture with notable achievements in revenue growth and new product launches, but is offset by challenges such as increased competition, supply disruptions, and decreased net income.Read More>---
AMPH Stock 12 Month Forecast
Average Price Target
$63.67
▲(78.55% Upside)
Technical Analysis
Amneal Pharmaceuticals
―
Catalyst Pharma
―
Pacira Pharmaceuticals
―
Dr Reddy's Laboratories
―
Supernus Pharmaceuticals
―
Kala Pharmaceuticals
―
Best Analysts Covering AMPH
1 Year
1 Year Success Rate
11/18 ratings generated profit
1 Year Average Return
+18.92%
assigned a buy rating 3 months ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +18.92% per trade.
---